Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration

Trial Profile

Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Cytarabine/daunorubicin (Primary) ; Anthracyclines; Cytarabine; Daunorubicin; Etoposide; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Celator Pharmaceuticals
  • Most Recent Events

    • 03 Jun 2013 Multivariate analysis of data from this study and study 204 (profile 700035990) was presented at the American Society of Clinical Oncology 2013 Annual Meeting (ASCO 2013), according to a Celator Pharmaceuticals media release.
    • 05 Jun 2012 Results from a subgroup analysis have been presented at ASCO-2012 according to a Celator media release.
    • 14 Dec 2011 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top